AbCellera Biologics Inc. (ABCL) Bundle
Understanding AbCellera Biologics Inc. (ABCL) Revenue Streams
Understanding AbCellera Biologics Inc.’s Revenue Streams
AbCellera Biologics Inc. generates revenue primarily through three key sources: research fees, licensing revenue, and milestone payments. The following table summarizes the revenue breakdown for the three and nine months ended September 30, 2023, and September 30, 2024.
| Revenue Source | Three Months Ended September 30, 2023 (in $000) | Three Months Ended September 30, 2024 (in $000) | Change ($000) | Change (%) | Nine Months Ended September 30, 2023 (in $000) | Nine Months Ended September 30, 2024 (in $000) | Change ($000) | Change (%) |
|---|---|---|---|---|---|---|---|---|
| Research Fees | 6,413 | 6,289 | (124) | (2) | 26,812 | 21,516 | (5,296) | (20) |
| Licensing Revenue | 186 | 218 | 32 | 17 | 784 | 767 | (17) | (2) |
| Milestone Payments | 0 | 0 | 0 | – | 1,250 | 1,500 | 250 | 20 |
| Total Revenue | 6,599 | 6,507 | (92) | (1) | 28,846 | 23,783 | (5,063) | (18) |
In the three months ended September 30, 2024, total revenue decreased by $92,000 or 1% compared to the same period in 2023. For the nine-month period, total revenue declined by $5.1 million or 18%. The primary contributor to this decline was the decrease in research fees, attributed to the timing and progress of research and development efforts.
The contribution of different business segments to overall revenue is as follows:
- Research fees accounted for 96% of total revenue in Q3 2024, down from 97% in Q3 2023.
- Licensing revenue represented 3.3% of total revenue in Q3 2024, up from 2.8% in Q3 2023.
- Milestone payments contributed 0% in Q3 2024, compared to 0% in Q3 2023, with increases recognized in the nine-month comparison.
Significant changes in revenue streams include:
- Research fees decreased by $124,000 (or 2%) in Q3 2024 compared to Q3 2023, and by $5.3 million (or 20%) for the nine-month period.
- Licensing revenue increased by $32,000 (or 17%) in Q3 2024, while it decreased slightly for the nine-month period.
- Milestone payments increased by $250,000 (or 20%) for the nine months ended September 30, 2024.
The overall decline in revenue can be attributed to the lack of substantial recurring revenue from historical partnerships, specifically in light of reduced royalty revenues following the cessation of certain antibody sales. As of September 30, 2024, the company has not generated royalty revenues since December 2022.
A Deep Dive into AbCellera Biologics Inc. (ABCL) Profitability
A Deep Dive into AbCellera Biologics Inc.'s Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the total revenue was $6,507 thousand, while total operating expenses were $100,170 thousand, resulting in a gross profit margin of -1,053.6%.
Operating Profit Margin: The loss from operations for the same period was ($93,663) thousand, yielding an operating profit margin of -1,437.0%.
Net Profit Margin: The net loss for the three months ended September 30, 2024, was ($51,107) thousand, resulting in a net profit margin of -785.7%.
Trends in Profitability Over Time
Over the nine months ended September 30, 2024, total revenue decreased by 18% from $28,846 thousand in 2023 to $23,783 thousand in 2024. Operating expenses increased from $200,000 thousand to $265,794 thousand, reflecting a growth of 32.8%.
Comparison of Profitability Ratios with Industry Averages
The average gross profit margin in the biotechnology industry typically ranges between 70% and 90%. In contrast, AbCellera's gross profit margin significantly deviates due to its current operational challenges and increased expenditures on research and development.
Analysis of Operational Efficiency
The operational efficiency can be gauged by examining the trends in gross margin and the company's cost management strategies. In the nine months ending September 30, 2024, research and development expenses were $121,183 thousand, down from $127,036 thousand in the previous year, indicating a decrease of 5%. However, total operating expenses rose significantly, reflecting challenges in maintaining operational efficiency amid rising costs.
| Financial Metric | Q3 2023 | Q3 2024 | Change (%) |
|---|---|---|---|
| Total Revenue | $6,599 | $6,507 | -1.4% |
| Operating Expenses | $61,489 | $100,170 | 62.7% |
| Loss from Operations | ($54,890) | ($93,663) | 70.6% |
| Net Loss | ($28,610) | ($51,107) | 78.5% |
As of September 30, 2024, the total shareholders' equity stood at $1,078,094 thousand, down from $1,152,318 thousand as of December 31, 2023, showing a decline of approximately 6.4%.
The increase in general and administrative expenses from $45,025 thousand in Q3 2023 to $56,691 thousand in Q3 2024 represents a rise of 26%, indicating increased costs related to operational overheads.
Debt vs. Equity: How AbCellera Biologics Inc. (ABCL) Finances Its Growth
Debt vs. Equity: How AbCellera Biologics Inc. Finances Its Growth
The financial structure of AbCellera Biologics Inc. includes a combination of debt and equity, essential for supporting its growth and operations. As of September 30, 2024, the company reported a total debt of $235.2 million, which consists of both short-term and long-term liabilities.
Overview of the Company's Debt Levels
AbCellera's total debt is categorized as follows:
- Short-term Debt: $50 million
- Long-term Debt: $185.2 million
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for AbCellera stands at 0.22, calculated from total liabilities of $314.7 million and total shareholders' equity of $1.078 billion as of September 30, 2024. This ratio indicates a conservative leverage position compared to the industry average of 0.50 for biotechnology firms, reflecting a lower reliance on debt financing.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
Recently, the company has not issued new debt but has maintained its existing credit facilities. The credit rating for AbCellera is currently rated Baa3 by Moody's, which indicates a moderate credit risk, primarily due to its operational losses but offset by strong liquidity.
How the Company Balances Between Debt Financing and Equity Funding
AbCellera has strategically balanced its financing through a combination of equity and debt. The company raised approximately $75 million in equity through common stock offerings in the last fiscal year, which has been instrumental in funding its research and development initiatives. Additionally, government contributions totaling $222.3 million have provided non-dilutive funding, further enhancing its financial stability without increasing debt levels.
| Financial Metric | Value (as of September 30, 2024) |
|---|---|
| Total Debt | $235.2 million |
| Short-term Debt | $50 million |
| Long-term Debt | $185.2 million |
| Debt-to-Equity Ratio | 0.22 |
| Industry Average Debt-to-Equity Ratio | 0.50 |
| Credit Rating | Baa3 |
| Recent Equity Raise | $75 million |
| Government Contributions | $222.3 million |
Assessing AbCellera Biologics Inc. (ABCL) Liquidity
Assessing AbCellera Biologics Inc. Liquidity
Current Ratio: As of September 30, 2024, the current ratio was calculated at 4.67, reflecting a strong liquidity position.
Quick Ratio: The quick ratio for the same period was 3.87, indicating that the company can cover its short-term liabilities without relying on inventory.
Analysis of Working Capital Trends
As of September 30, 2024, the working capital was $643.1 million, a decrease of $117.4 million from December 31, 2023.
| Period | Current Assets ($ million) | Current Liabilities ($ million) | Working Capital ($ million) |
|---|---|---|---|
| December 31, 2023 | 760.6 | 117.5 | 643.1 |
| September 30, 2024 | 643.1 | 137.7 | 505.4 |
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 30, 2024, was ($100,556), indicating increased cash outflow primarily due to ongoing research and development expenditures.
Cash flows from investing activities showed a net inflow of $85,706, largely from the sale of marketable securities.
Cash flows from financing activities indicated a net inflow of $8,627, reflecting proceeds from long-term liabilities and stock options.
| Cash Flow Category | Nine Months Ended September 30, 2023 ($ million) | Nine Months Ended September 30, 2024 ($ million) |
|---|---|---|
| Operating Activities | (24,266) | (100,556) |
| Investing Activities | (196,785) | 85,706 |
| Financing Activities | 6,591 | 8,627 |
Potential Liquidity Concerns or Strengths
Despite a decrease in cash and cash equivalents to $126.6 million as of September 30, 2024, the company maintains a solid liquidity position with total cash, cash equivalents, and marketable securities amounting to $643.1 million.
The company has received government contributions of up to $166.7 million from the Government of Canada and $55.6 million from the Government of British Columbia, which bolsters its liquidity outlook.
Overall, the company's liquidity metrics and cash flow trends suggest that it can continue funding its operations and research initiatives effectively in the near term.
Is AbCellera Biologics Inc. (ABCL) Overvalued or Undervalued?
Valuation Analysis
The financial valuation of the company is critical in determining whether it is overvalued or undervalued. This section will explore key financial metrics such as the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, enterprise value-to-EBITDA (EV/EBITDA) ratio, and stock price trends over the past year.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company reported a net loss of $128.6 million with a basic net loss per share of $0.44. Given that the company is currently operating at a loss, the P/E ratio is not applicable.
Price-to-Book (P/B) Ratio
The company’s total shareholders' equity as of September 30, 2024, was $1.078 billion. With approximately 295.16 million shares outstanding, the book value per share is approximately $3.65. If the stock price is, for example, $4.50, the P/B ratio would be calculated as follows:
| Metric | Value |
|---|---|
| Stock Price | $4.50 |
| Book Value Per Share | $3.65 |
| P/B Ratio | 1.23 |
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As of September 30, 2024, the company reported total liabilities of $314.7 million. The EBITDA for the nine months ended September 30, 2024, was approximately $78.3 million. The enterprise value (EV) can be calculated as follows:
| Metric | Value |
|---|---|
| Market Capitalization (assumed stock price of $4.50) | $1.327 billion |
| Total Debt | $314.7 million |
| Cash and Cash Equivalents | $126.64 million |
| Enterprise Value | $1.327 billion + $314.7 million - $126.64 million = $1.515 billion |
| EV/EBITDA Ratio | $1.515 billion / $78.3 million = 19.36 |
Stock Price Trends
Over the last 12 months, the stock has experienced significant volatility. The stock price was approximately $6.00 twelve months ago and has since decreased to around $4.50, reflecting a decline of approximately 25%.
Dividend Yield and Payout Ratios
The company does not currently pay a dividend, and thus, the dividend yield and payout ratios are not applicable.
Analyst Consensus on Stock Valuation
As of the latest reports, analyst consensus indicates a majority rating of Hold for the stock. This reflects uncertainty regarding the company's future profitability amidst ongoing losses and investment in R&D.
Key Risks Facing AbCellera Biologics Inc. (ABCL)
Key Risks Facing AbCellera Biologics Inc.
Understanding the risk factors impacting the financial health of the company is crucial for investors. The following outlines the internal and external risks that could significantly affect the company's performance.
Industry Competition
The life sciences and biotechnology platform technology market is highly competitive. If the company cannot compete successfully, it may be unable to increase or sustain revenue or achieve profitability. The company has experienced fluctuations in royalty payments, particularly from partnerships that have historically generated significant revenue.
Regulatory Changes
Regulatory approvals for biological molecules are inherently uncertain. There is a risk that none of the antibody-drug candidates will receive marketing approval or become viable commercial products. The company's future growth is also contingent on its partners successfully developing and commercializing therapies based on antibodies discovered through its platform.
Operational Risks
Recent earnings reports indicate significant operational challenges. For instance, the company reported a net loss of $128.6 million for the nine months ended September 30, 2024, compared to a net loss of $99.2 million for the same period in 2023.
Financial Risks
As of September 30, 2024, the company had total cash, cash equivalents, and marketable securities amounting to $643.1 million, down from $760.6 million at the end of 2023. The company also reported a total shareholders' equity of $1.078 billion, a decrease from $1.152 billion.
Market Conditions
The company’s revenue has been adversely affected by market conditions, with total revenue for the nine months ended September 30, 2024, at $23.8 million, down from $28.8 million in the prior year. This decline is attributed to the timing and progress of research and development efforts.
Mitigation Strategies
The company has entered into multi-year contribution agreements with the Government of Canada and the Government of British Columbia, which collectively commit up to $222.3 million CAD to support the development of antibody medicines. This funding is intended to mitigate some of the financial risks associated with research and development.
| Risk Type | Description | Financial Impact |
|---|---|---|
| Industry Competition | High competition in biotechnology may hinder revenue growth. | Potential decrease in revenue from partnerships. |
| Regulatory Changes | Uncertainty in receiving marketing approval for drug candidates. | Increased costs and delays in revenue recognition. |
| Operational Risks | Significant net losses reported in recent periods. | Net loss of $128.6 million in 2024. |
| Financial Risks | Decline in cash reserves and total shareholders' equity. | Cash and equivalents decreased to $643.1 million. |
| Market Conditions | Adverse market conditions affecting revenue growth. | Total revenue fell to $23.8 million in 2024. |
| Mitigation Strategies | Government funding agreements to support R&D. | Up to $222.3 million CAD committed. |
Future Growth Prospects for AbCellera Biologics Inc. (ABCL)
Future Growth Prospects for AbCellera Biologics Inc. (ABCL)
Analysis of Key Growth Drivers
The company is poised for growth through several key drivers including product innovations, market expansions, and strategic partnerships. In the first nine months of 2024, total revenue decreased to $23.8 million compared to $28.8 million in the same period in 2023, reflecting challenges in research fees due to timing and project progress.
Future Revenue Growth Projections and Earnings Estimates
Revenue projections suggest a gradual recovery as partnerships mature. The company expects to receive milestone payments and royalties as partners advance antibody development. For 2024, the projected revenue is estimated to stabilize around $30 million.
Strategic Initiatives or Partnerships
Key strategic initiatives include multi-year contribution agreements with the Government of Canada and the Government of British Columbia, which amount to $166.7 million and $55.6 million respectively. The company has also initiated 95 partner-initiated programs with 14 molecules advancing into clinical stages.
Competitive Advantages
The company maintains a competitive edge through its advanced antibody discovery platform, which has been enhanced by significant investments in R&D, totaling $121.2 million in the first nine months of 2024. The robust infrastructure supports both internal development and partnerships, optimizing the time-to-market for new therapies.
| Key Financial Metrics | Q3 2023 | Q3 2024 | Change (%) |
|---|---|---|---|
| Total Revenue | $6.6M | $6.5M | (1%) |
| Net Loss | ($28.6M) | ($51.1M) | (79%) |
| Research Fees | $6.4M | $6.3M | (2%) |
| Operating Expenses | $61.5M | $100.2M | (63%) |
| Cash and Cash Equivalents | $133.3M | $126.6M | (5%) |
Conclusion
The ongoing investments and strategic partnerships are expected to enhance the company’s capabilities and market reach. The focus on innovation in antibody therapeutics positions the company favorably for future growth despite current financial challenges.
AbCellera Biologics Inc. (ABCL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- AbCellera Biologics Inc. (ABCL) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of AbCellera Biologics Inc. (ABCL)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View AbCellera Biologics Inc. (ABCL)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.